uniQure N.V. Licenses Revenue (Deprecated 2018-01-31)
uniQure N.V. (QURE) reported Licenses Revenue (Deprecated 2018-01-31) of $8.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-14.
Discontinued › Income Statement › Other Income
us-gaap:LicensesRevenue · last filed 2018-03-14
- uniQure N.V. licenses revenue (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $0.00, a 100.00% decline year-over-year.
- uniQure N.V. licenses revenue (deprecated 2018-01-31) for the quarter ending 2017-03-31 was $234.00K, a 2.90% decline year-over-year.
- uniQure N.V. licenses revenue (deprecated 2018-01-31) for the quarter ending 2016-12-31 was $239.00K.
- uniQure N.V. licenses revenue (deprecated 2018-01-31) for the quarter ending 2016-09-30 was $246.00K.
- uniQure N.V. licenses revenue (deprecated 2018-01-31) for fiscal 2017 was $8.00K, a 99.18% decline from fiscal 2016.
- uniQure N.V. licenses revenue (deprecated 2018-01-31) for fiscal 2016 was $975.00K.
| Period end | Licenses Revenue (Deprecated 2018-01-31) 3 month | Licenses Revenue (Deprecated 2018-01-31) 6 month | Licenses Revenue (Deprecated 2018-01-31) 9 month | Licenses Revenue (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $8.00K 10-K · filed 2018-03-14 | ||
| 2017-09-30 | $8.00K 10-Q · filed 2017-11-01 | |||
| 2017-03-31 | $234.00K 10-Q · filed 2017-05-09 | $473.00K derived: sum of 2 quarters · filed 2018-03-14 | $719.00K derived: sum of 3 quarters · filed 2018-03-14 | |
| 2016-12-31 | $239.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $485.00K derived: sum of 2 quarters · filed 2018-03-14 | $975.00K 10-K · filed 2018-03-14 | |
| 2016-09-30 | $246.00K 10-Q · filed 2017-11-01 | $736.00K 10-Q · filed 2017-11-01 | ||
| 2016-03-31 | $241.00K 10-Q · filed 2017-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |